Christine Grogan Joins New Horizon Medical Solutions as CCO

New Horizon Medical Solutions (NHMS) has welcomed Dr. Christine Grogan as its chief commercial officer (CCO).

Dr. Grogan is an authentic yet results-driven executive with an established reputation for transforming organizations and delivering sustained revenue growth. With extensive experience across the pharmaceutical, biotech, and medical device arenas, she has successfully led teams, developed integrated go-to-market strategies, and forged strategic partnerships that unlock long-term value.

“Christine is a decisive leader with the strategic clarity and operational focus we need at this stage,” New Horizon Medical Solutions CEO Will Hall said. “She understands how to translate market insight into results, and how to build teams that deliver. We’re excited to have her on board.”

As chief commercial officer, Dr. Grogan will lead all facets of the Las Vegas-based company’s commercial organization, including sales, marketing, strategic partnerships, and customer engagement. She will play a pivotal role in advancing New Horizon Medical Solutions’ growth agenda, strengthening market positioning, and ensuring the delivery of differentiated value to clients, providers, and patients.

Dr. Grogan has held senior leadership roles in growth-oriented healthcare organizations, where she consistently delivered measurable gains in revenue and market share while strengthening customer relationships and commercial infrastructure.

“I’m excited to join New Horizon Medical Solutions at a pivotal moment,” Dr. Grogan stated. “The company has a clear vision and strong momentum. I look forward to building on that foundation while expanding our reach, deepening our relationships with healthcare providers, and philanthropic endeavors.”

New Horizons Medical Solutions specializes in advanced wound care technologies, committed to developing and delivering biologically derived human placental allograft products that meet the highest safety and performance standards. NHMS’s product portfolio includes amniotic membranes, placental tissues, wound care devices, and skin grafts for chronic wounds, surgical reconstruction, burns, and orthopedic procedures. Through evidence-based design and precision manufacturing, NHMS strives to enhance patient outcomes in clinical practice. In addition, NHMS is committed to advancing patient care through community partnerships that drive meaningful, lasting impact.